Chinese life sciences companies are expanding globally due to regulatory reforms and licensing deals. Despite growth, operational hurdles remain for sponsors. Industry leaders at a conference in Suzhou discussed strategies to overcome challenges and build trust in China’s clinical research capabilities. China leads the world in clinical trial activity, surpassing the US in total trials. Reforms aim to align China with international standards, but logistical and operational challenges persist. Chinese biotechs face obstacles in international trials, including communication and cultural differences. Trust in China’s clinical research depends on data quality and regulatory transparency. China’s biotech sector is at a pivotal point, with the need to navigate challenges and build global-ready teams for success in international trials.

Read more at Yahoo Finance: China’s biotechs navigate the demands of international trials